Pharmakon Advisors

110 East 59TH Street
New York, NY 10022-1304

Website: pharmakonadvisors.com

Firm Size

• Assets Under Management (AUM):$1.8 Billion
• Number of Funds:1
• Employees:12
• Firm Type:Private Equity
• Focus Areas: Software & Technology
  Services
  Healthcare
  

Description

Pharmakon Advisors, LP is a renowned investment management firm based in New York, NY. The company focuses on providing strategic advice and investment solutions in the healthcare industry. With a strong background in life sciences and pharmaceuticals, Pharmakon Advisors offers clients a deep understanding of the complexities and opportunities within the healthcare sector. As an advisory firm, Pharmakon Advisors assists clients in making informed investment decisions, guiding them through various stages of the investment process. Their expertise spans across biotechnology, pharmaceuticals, medical technology, and healthcare services, and their knowledge of the market dynamics helps clients navigate through potential risks and maximize returns on their investments. Pharmakon Advisors is committed to delivering tailored investment strategies that align with each client's specific goals and risk tolerance. They provide personalized insights and comprehensive research to support their investment recommendations. Using a data-driven approach, the firm leverages their industry expertise to identify growth opportunities and potential investment targets. The company's team consists of highly skilled professionals with extensive experience in the healthcare and investment fields. Their collective knowledge and deep network within the industry allow them to stay ahead of emerging trends and technological advancements. By leveraging this expertise, Pharmakon Advisors aims to provide their clients with a competitive advantage in the healthcare investment landscape. Overall, Pharmakon Advisors, LP is a highly reputable investment management firm that specializes in providing strategic advice and investment solutions in the healthcare space. With their expertise and commitment to excellence, they strive to help clients navigate the complex healthcare industry and achieve their investment objectives.

Latest News

Powered by

Nov 02, 2023: Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has amended the terms of its loan agreement with Pharmakon Advisors, LP, the investment manager of the BioPharma Credit funds that it originally entered into in November 2019 . The amendment extends the maturity date of the loan to March of 2025 from November 11, 2024 . Under the terms of the amendment, Akebia's quarterly principal payments have been deferred until October 31, 2024 at which time the company will begin making monthly principal payments. Details of the amended agreement are provided in the Form 8K filed on November 2, 2023 .